BLNK (phospho Tyr84) Polyclonal Antibody

    • Catalog No.:YP0802
    • Applications:WB;IHC;IF;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • BLNK
      • Fields:
      • >>NF-kappa B signaling pathway;>>Osteoclast differentiation;>>B cell receptor signaling pathway;>>Epstein-Barr virus infection;>>Primary immunodeficiency
      • Gene Name:
      • BLNK
      • Protein Name:
      • B-cell linker protein
      • Human Swiss Prot No:
      • Q8WV28
      • Mouse Swiss Prot No:
      • Q9QUN3
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human BLNK around the phosphorylation site of Tyr84. AA range:50-99
      • Specificity:
      • Phospho-BLNK (Y84) Polyclonal Antibody detects endogenous levels of BLNK protein only when phosphorylated at Y84.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:10000.. IF 1:50-200
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • BLNK;BASH;SLP65;B-cell linker protein;B-cell adapter containing a SH2 domain protein;B-cell adapter containing a Src homology 2 domain protein;Cytoplasmic adapter protein;Src homology 2 domain-containing leukocyte protein of 65 kDa;
      • Observed Band(KD):
      • 65kD
      • Background:
      • This gene encodes a cytoplasmic linker or adaptor protein that plays a critical role in B cell development. This protein bridges B cell receptor-associated kinase activation with downstream signaling pathways, thereby affecting various biological functions. The phosphorylation of five tyrosine residues is necessary for this protein to nucleate distinct signaling effectors following B cell receptor activation. Mutations in this gene cause hypoglobulinemia and absent B cells, a disease in which the pro- to pre-B-cell transition is developmentally blocked. Deficiency in this protein has also been shown in some cases of pre-B acute lymphoblastic leukemia. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, May 2012],
      • Function:
      • disease:Defects in BLNK are the cause of hypoglobulinemia and absent B-cells [MIM:604515]. This is a developmental blockage at the pro- to pre-B-cell transition.,disease:In 6 of 34 childhood pre-B acute lymphoblastic leukemia (ALL) samples that were tested showed a complete loss or drastic reduction of BLNK expression.,function:Functions as a central linker protein that bridges kinases associated with the B-cell receptor (BCR) with a multitude of signaling pathways, regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR-mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR-mediated ac
      • Subcellular Location:
      • Cytoplasm . Cell membrane . BCR activation results in the translocation to membrane fraction.
      • Expression:
      • Expressed in B-cell lineage and fibroblast cell lines (at protein level). Highest levels of expression in the spleen, with lower levels in the liver, kidney, pancreas, small intestines and colon.
      • Products Images
      • Immunohistochemistry analysis of paraffin-embedded human brain, using BLNK (Phospho-Tyr84) Antibody. The picture on the right is blocked with the phospho peptide.
      • Western blot analysis of lysates from K562 cells treated with starved 24h, using BLNK (Phospho-Tyr84) Antibody. The lane on the right is blocked with the phospho peptide.